News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytRx Corporation (CYTR) Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial With Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer


2/28/2013 9:48:11 AM

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that enrollment of 140 evaluable patients has been completed in the Company’s global Phase 2b clinical trial with its oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). “Tamibarotene could represent a multi-billion dollar market opportunity as a breakthrough in the treatment of NSCLC,” said CytRx CEO Steven A. Kriegsman. “We are delighted to have reached this major milestone in the clinical trial and expect to report top-line results from this trial in the second half of this year.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES